This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B21.7 (HIV disease resulting in multiple malignant neoplasms) | Special Copayment Reduction: V103 (severe intractable disease, 5 years) |
| B. Synonyms | HIV disease resulting in multiple malignant neoplasms; AIDS with multiple cancers; HIV-associated polyclonal malignancy |
| C. Adult onset | Likelihood of adult onset: very high — B21.7 codes the occurrence of two or more different malignant neoplasms, simultaneously or sequentially, in an HIV-infected individual. Simultaneous occurrence of multiple cancers occurs mainly in adults (40s–60s), in long-term HIV-infected individuals or patients who live longer after ART. |
| 1. History | Before ART: simultaneous occurrence of AIDS-defining malignancies such as KS + lymphoma was not uncommon. After ART: with longer lifespan, simultaneous occurrence of AIDS-defining + non-AIDS-defining malignancies has increased. Coexistence of non-AIDS-defining malignancies (liver cancer, lung cancer, anal cancer, oropharyngeal cancer, etc.) and AIDS-defining malignancies is a clinical challenge. |
| 2. Causes | Combined action of HIV-induced immunosuppression + oncogenic viruses (HHV-8, EBV, HPV, HBV, HCV). Promotion of carcinogenesis in multiple organs by chronic immune activation. Overlapping lifestyle risk factors such as smoking and alcohol use. |
| 3. Genetics | Accumulation of DNA damage and abnormal repair mechanisms due to chronic HIV immune activation. In HPV-related cancers (cervical, anal, and oropharyngeal cancer), inhibition of p53 and pRb by the HPV genes E6/E7 is the tumorigenic mechanism. Different molecular pathways transform independently in multiple cancers. |
| 4. General epidemiology | After ART, the proportion of non-AIDS-defining malignancies among cancer-related causes of death in HIV-infected individuals has increased. Liver cancer (HBV/HCV co-infection), lung cancer (smoking), and anal cancer (HPV) carry a 5–30-fold increased risk in HIV-infected individuals compared with the general population. The risk of simultaneous multiple cancers is higher than in the general population. |
| 5. Pathophysiology | Impaired tumor surveillance owing to HIV-induced decline of cytotoxic T-cell function. Increased oxidative stress and DNA damage from chronic immune activation. Co-expression of infection and oncogenic potential of tumor viruses (HHV-8, EBV, HPV, HBV, HCV) in multiple organs. |
| 6. Symptoms | The characteristic symptoms of each malignant neoplasm appear simultaneously or overlap. Generalized wasting, fever, and weight loss are common. A complex clinical picture in which AIDS-defining malignancies (KS, NHL) and non-AIDS-defining malignancies (lung cancer, liver cancer, anal cancer) coexist. |
| 7. Signs | Abnormal findings in multiple organs, elevated multiple tumor markers, multiple areas of increased FDG uptake on PET-CT. Overlap of the imaging and laboratory findings specific to each malignant neoplasm. |
| 8. Screening | Cancer screening in HIV-infected individuals by age and risk factor: cervical cancer (Pap smear/HPV test), anal cancer (anal cytology), liver cancer (AFP + liver ultrasound, in HBV/HCV-infected individuals), lung cancer (low-dose CT, in smokers), colorectal cancer (colonoscopy). |
| 9. Diagnosis | Perform individual diagnostic tests for each malignant neoplasm. PET-CT is useful for simultaneous detection of multiple malignant neoplasms. Biopsy and histopathologic confirmation of each lesion are necessary. Molecular characteristics of individual tumors are identified with tumor gene panel testing. |
| 10. Treatment | ART-based immune recovery. Individualized treatment plan for each malignant neoplasm (multidisciplinary approach essential). Determining treatment priority among multiple cancers: treat the most life-threatening malignant neoplasm first. Management of the complexity of drug interactions. |
| 11. Prognosis | The prognosis of HIV patients with multiple malignant neoplasms is markedly worse than with a single malignant neoplasm. The type and stage of each malignant neoplasm, patient performance status, and CD4 count jointly determine prognosis. |
| 12. Prevention | Early ART initiation and continuation. HPV vaccine (prevention of cervical and anal cancer), HBV vaccine. Smoking cessation (prevention of lung and oropharyngeal cancer). HCV treatment (prevention of liver cancer). Adherence to regular cancer screening protocols. |
| 13. References | Silverberg MJ et al. Ann Intern Med 2015 and 9 others |
In the relationship between HIV infection and malignant neoplasms, the B21.7 code, which covers multiple malignant neoplasms, is clinically important but a relatively understudied category. In the pre-ART era, simultaneous occurrence of Kaposi's sarcoma (KS) and non-Hodgkin lymphoma (NHL) was not uncommon. In the state of severe immunosuppression, HHV-8 (the cause of KS) and EBV (a co-cause of NHL) acted together to produce multiple AIDS-defining malignant neoplasms.
With the great extension of lifespan of HIV-infected individuals since the introduction of ART, the pattern of multiple malignant neoplasms has changed. The occurrence of AIDS-defining malignancies (KS, NHL) has decreased, while the occurrence of non-AIDS-defining cancers (NADC)—liver cancer, lung cancer, anal cancer, cervical cancer, head and neck cancer, etc.—has increased. In long-term HIV survivors, a pattern of second malignancies or new primary malignancies after treatment of AIDS-defining malignancies has also increased. Against this background, B21.7 is a clinically important code reflecting the occurrence of multiple HIV-related malignancies in the ART era. A large cohort study by Silverberg et al. in 2015 reported that the incidence of various non-AIDS-defining malignancies in HIV-infected individuals can be 2 to 100 times that of the general population.
The cause of HIV disease resulting in multiple malignant neoplasms is that multiple mechanisms of tumor development, with HIV immunosuppression as the common background, act simultaneously or sequentially in multiple organs.
HHV-8 (cause of KS and PEL), EBV (NHL, Hodgkin lymphoma), high-risk HPV types (cervical, anal, and oropharyngeal cancer), and HBV and HCV (hepatocellular carcinoma) may be present simultaneously in HIV-infected individuals. Multiple malignant neoplasms arise when each virus independently activates carcinogenic mechanisms in different organs. HIV itself simultaneously weakens immune surveillance against multiple tumor viruses, amplifying the risk of multiple malignancies.
Chronic systemic immune activation from HIV infection accumulates DNA damage in multiple organs through sustained oxidative stress and overproduction of inflammatory cytokines. This does not completely normalize even after viral suppression by ART, and is one of the reasons why cancer risk remains persistently high in HIV-infected individuals.
In HIV-infected individuals, lifestyle risk factors such as smoking, heavy drinking, and drug use are more frequent than in the general population, and these further raise the risk of many cancers such as lung, head and neck, liver, and bladder cancer. In the development of multiple malignant neoplasms, the additive effect of lifestyle factors and immunosuppression operates.
In multiple malignant neoplasms, each tumor has an independent molecular origin, though some common oncogenic mutations (e.g., loss of p53 function) may be shared. In HPV-related cancers (anal, cervical, and oropharyngeal cancer), degradation of p53 by the HPV E6 protein and inhibition of pRb function by the E7 protein cause cell-cycle dysregulation. There are reports that the efficiency of DNA repair mechanisms (especially the homologous recombination pathway) is reduced in chronic HIV infection, which may cause genomic instability vulnerable to the development of multiple cancers. In GWAS (genome-wide association studies), loci such as HCP5 and PSORS1C1 are associated with HIV susceptibility, and some may also be related to increased cancer risk. In individual malignant neoplasms, somatic mutations, copy number variations, and methylation abnormalities accumulate independently to drive the development of each tumor.
The overall cancer incidence in HIV-infected individuals remains 2–4 times higher than in the general population even after ART. According to the North American AIDS Cohort Collaboration study published in 2015 (including more than 220,000 HIV-infected individuals), the standardized incidence ratios (SIR) for non-AIDS-defining malignancies in HIV-infected individuals were 2.6 for lung cancer, 19 for anal cancer, 5 for liver cancer, 2.1 for oropharyngeal cancer, and 7–11 for Hodgkin lymphoma. The probability of simultaneous occurrence of multiple malignant neoplasms increases multiplicatively as the incidence of each individual malignancy increases. With the increase in HIV-infected individuals living longer on ART, the clinical incidence of second cancers or simultaneous multiple cancers is expected to increase.
HIV-induced immunosuppression provides the foundation on which multiple tumor viruses and carcinogenic mechanisms are activated simultaneously. Decreased CD4+ T cells and reduced CD8+ CTL function simultaneously impair immune surveillance against HHV-8-, EBV-, and HPV-infected cells. Persistent immune activation from chronic HIV infection chronically activates the NF-κB, MAPK, and PI3K-Akt pathways, creating an environment of promoted cell proliferation, anti-apoptotic signaling, and promoted angiogenesis. This environment permits clonal growth of precancerous cells in multiple tissues. Studies also show that the HIV Tat protein activates the Wnt/β-catenin and HIF-1α pathways, promoting proliferation and survival of tumor cells. In addition, collapse of gut mucosal immunity by HIV and microbial translocation sustain systemic inflammation, keeping cancer risk high in multiple organs in the long term.
The clinical symptoms of B21.7 vary widely depending on the types of coexisting malignant neoplasms and the organs involved. The characteristic symptoms of each malignant neoplasm appear simultaneously or overlap, with HIV-related systemic symptoms (fever, weight loss, extreme fatigue) in common as the background. KS + NHL coexisting: purple KS lesions of the skin and mucosa + rapidly growing lymphadenopathy and abdominal mass. KS + lung cancer coexisting: skin KS lesions + cough, bloody sputum, chest pain, and dyspnea. NHL + anal cancer coexisting: abdominal mass and lymphadenopathy + anal pain, bloody stool, and anal mass. When multiple malignant neoplasms coexist, symptoms of another malignant neoplasm worsen or newly appear during treatment of one, complicating the clinical course.
Abnormal findings appear simultaneously in multiple organs. Coexistence of skin KS lesions and lymphadenopathy, elevated cancer markers of multiple organs (AFP, CEA, LDH, β2-microglobulin), multiple FDG-avid lesions on PET-CT, and multiple abnormal imaging findings (chest nodules + abdominal mass, etc.) are characteristic. Cytopenia (bone marrow involvement or chemotherapy toxicity), liver function abnormalities (liver involvement), and renal function abnormalities (renal involvement or drug toxicity) may accompany.
For early detection of multiple malignant neoplasms in HIV-infected individuals, a comprehensive cancer screening program according to age and risk factors is recommended. Cervical cancer: HPV/Pap smear at diagnosis in all HIV-infected women, then annually. Anal cancer: anal cytology (including high-resolution anoscopy) in MSM, those with high-risk HPV exposure, and CD4 <200/μL. Liver cancer: AFP + liver ultrasound every 6 months in patients co-infected with HBV or HCV. Lung cancer: annual low-dose CT in HIV-infected individuals aged 55 or older who smoke (30 pack-years or more). Cutaneous KS: regular skin examination in all HIV patients. Lymphoma: regular weight measurement, lymph node palpation, and LDH measurement.
Individual confirmatory tests are performed for each malignant neoplasm. PET-CT is useful for identifying multiple whole-body lesions simultaneously and may suggest the presence of multiple malignant neoplasms. However, individual biopsy of each lesion is needed to determine which of the several malignant neoplasms a single PET-CT lesion is attributable to. When multiple malignant neoplasms are suspected, a multidisciplinary approach (medical oncology, surgery, radiation oncology, hematology, infectious diseases) is essential. The following standard diagnostic tests are performed for each tumor: blood tumor marker panel, imaging (CT, MRI, PET-CT), tissue biopsy (each lesion). Gene expression profiling and next-generation sequencing (NGS) are useful for identifying molecular characteristics and treatment targets of multiple malignant neoplasms.
A multidisciplinary approach is essential in treating multiple malignant neoplasms, following these principles. First, optimize ART to restore immune function as much as possible and improve treatment tolerance. Second, as treatment priority, treat the most life-threatening malignant neoplasm first, but treat two tumors simultaneously when possible. Third, manage closely the interactions among anticancer drugs and with ART. For example, combining ritonavir-based ART with vincristine increases vincristine toxicity, so switching to integrase inhibitor-based ART may be needed. KS + NHL coexisting: liposomal doxorubicin for KS + R-CHOP/EPOCH for NHL. In this case doxorubicin is used in common for the treatment of both malignant neoplasms. HPV-related anal and cervical cancer: concurrent chemoradiotherapy with radiation + cisplatin is standard and can be combined with ART. Hepatocellular carcinoma: resection, radiofrequency ablation, transarterial chemoembolization (TACE), sorafenib/lenvatinib, etc., according to HCC stage.
The prognosis of HIV-infected individuals with multiple malignant neoplasms is markedly worse than with a single malignant neoplasm. The stage, histologic type, and treatment response of each malignant neoplasm, CD4 count, and patient performance status jointly determine prognosis. Cumulative treatment toxicity, complications from immunosuppression, and problems with treatment adherence may further worsen prognosis. However, there are reports that long-term survival is possible when immune recovery by ART is sufficient and each malignant neoplasm is diagnosed at a stage sensitive to treatment. Even when one of the multiple malignant neoplasms achieves complete remission, continued management of the remaining malignant neoplasms is needed.
Integrated prevention that applies the prevention strategies for all the individual malignant neoplasms is needed. Maintaining CD4 through ART (restoring immune surveillance, reducing overall cancer risk). HPV vaccine (ages 26 and under: standard; ages 27–45: shared decision-making) to prevent HPV-related anal, cervical, and oropharyngeal cancer. HBV vaccine (for the uninfected) and treatment with HCV direct-acting antivirals (DAAs) to prevent hepatocellular carcinoma. Smoking cessation (prevention of lung, head and neck, and bladder cancer). Limiting alcohol intake (prevention of liver and head and neck cancer). Early detection and treatment through regular cancer screening. It is important to include cancer prevention and screening as a core element of integrated health care programs for HIV-infected individuals.
Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163(7):507-518. DOI: 10.7326/M14-2768. PMID: 26167721.
Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Cancer risk in HIV-infected persons in Europe. Lancet Oncol. 2009;10(10):991-1001. DOI: 10.1016/S1470-2045(09)70262-2. PMID: 19818685.
Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425-432. DOI: 10.1093/jnci/dji072. PMID: 15770005.
Bower M, Powles T. HIV-associated cancers. Hematol Oncol Clin North Am. 2008;22(4):745-766. DOI: 10.1016/j.hoc.2008.04.001. PMID: 18638694.
Park LS, Tate JP, Sigel K, et al. Association of viral suppression with lower AIDS-defining and non-AIDS-defining cancer incidence in HIV-infected veterans: a prospective cohort study. Ann Intern Med. 2018;169(2):87-96. DOI: 10.7326/M17-2927. PMID: 29946680.
Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52(5):611-622. DOI: 10.1097/QAI.0b013e3181b327ca. PMID: 19770804.
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525-1533. DOI: 10.1016/S0140-6736(13)61809-7. PMID: 24152939.
Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-defining and non-AIDS-defining conditions. Cancer Res. 2001;61(22):8289-8293. PMID: 11719462.
WHO. Guidelines on HIV-related cancer prevention, treatment and surveillance. WHO. 2022. ISBN: 9789240046085.
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59-67. DOI: 10.1016/S0140-6736(07)61050-2. PMID: 17617273.